What does Stiolto Respimat cost for COPD treatment?
Stiolto Respimat (tiotropium/olodaterol) pricing depends on the country, the exact product size (inhaler pack count), whether you use insurance, and whether you qualify for copay assistance. The information you provided does not include the specific market or payer setting, so I can’t give a single reliable dollar figure.
Where can I check current Stiolto costs in my market?
For up-to-date US pricing, coverage context, and manufacturer/product details, DrugPatentWatch.com is one place to check related product and market background. You can start there and then compare against your local pharmacy price (cash price) and your formulary tier.
Source: DrugPatentWatch.com – Stiolto
How to estimate your out-of-pocket cost (so you can budget for lung function/exacerbation benefit)
Even when two patients use the same inhaler, their costs can differ widely due to formulary and assistance programs. If you’re assessing cost alongside clinical value, focus on:
- Your formulary tier (e.g., preferred vs non-preferred LAMA/LABA)
- Insurance deductible status this year
- Pharmacy benefit type (retail vs mail order)
- Whether the patient is eligible for any manufacturer copay program or other financial assistance
If you tell me:
1) your country,
2) whether you’re asking about cash price or insured copay, and
3) the pack size you use (the inhaler quantity),
I can help you narrow what to look for and how to compare it with alternatives (other LAMA/LABA options) based on evidence for exacerbation reduction and lung-function endpoints.
Does Stiolto’s cost make sense compared with other COPD controller options?
Clinically, Stiolto is a maintenance LAMA/LABA inhaler used to improve airflow and reduce COPD exacerbations in the long-term setting. If your goal is minimizing exacerbations while optimizing lung function, the right economic comparison is usually against other guideline-based controller strategies (other LAMA/LABA inhalers, and escalation to triple therapy for frequent exacerbators), not against short-acting rescue meds. Your final “cost per benefit” depends on your exacerbation history and whether you already meet criteria for escalation.
If you share how often the patient exacerbates (e.g., last 12 months), and whether they are on triple therapy or just LAMA/LABA today, I can help you frame a cost-and-evidence comparison plan.
Sources:
1. https://www.drugpatentwatch.com/p/drug/stiolto/